Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
Health
Joseph James

Real World Study Tracked Lecanemab Outcomes Three Years After Approval Across Diverse United States Clinical Settings

What the Study Reported

Three years after lecanemab became the first anti-amyloid antibody granted traditional FDA approval, its manufacturers have released data on how it has performed outside a clinical trial.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.